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ABSTRACT
Introduction: There are 11 500 rectal cancers
diagnosed annually in the UK. Although surgery
remains the primary treatment, there is evidence that
preoperative radiotherapy (RT) improves local
recurrence rates. High-quality surgery in rectal cancer
is equally important in minimising local recurrence.
Advances in MRI-guided prediction of resection margin
status and improvements in abdominoperineal excision
of the rectum (APER) technique supports a
reassessment of the contribution of preoperative RT.
A more selective approach to RT may be appropriate
given the associated toxicity.
Methods and analysis: This trial will explore the
feasibility of a definitive trial evaluating the omission of
RT in resectable low rectal cancer requiring APER. It
will test the feasibility of randomising patients to (1)
standard care (neoadjuvant long course RT
±chemotherapy and APER, or (2) APER surgery alone
for cT2/T3ab N0/1 low rectal cancer with clear
predicted resection margins on MRI. RT schedule will
be 45 Gy over 5 weeks as current standard, with
restaging and surgery after 8–12 weeks. Recruitment
will be for 24 months with a minimum 12-month
follow-up.
Objectives: Objectives include testing the ability to
recruit, consent and retain patients, to quantify the
number of patients eligible for a definitive trial and to
test feasibility of outcomes measures. These include
locoregional recurrence rates, distance to
circumferential resection margin, toxicity and surgical
complications including perineal wound healing, quality
of life and economic analysis. The quality of MRI
staging, RT delivery and surgical specimen quality will
be closely monitored.
Ethics and dissemination: The trial is approved by
the Regional Ethics Committee and Health Research
Authority (HRA) or equivalent. Written informed
consent will be obtained. Serious adverse events will
be reported to Swansea Trials Unit (STU), the ethics
committee and trial sites. Trial results will be
submitted for peer review publication and to trial
participants.
Trial registration number: ISRCTN02406823.
INTRODUCTION
There are 11 500 rectal cancers diagnosed
annually in the UK.1 Surgery following pre-
operative long course radiotherapy (RT) has
been the treatment of choice up until now,2
but recent advances in surgical technique
and better MRI-guided prediction of resec-
tion margins now suggest that in patients
with locally advanced low rectal cancer,
surgery alone may be sufﬁcient to minimise
local recurrence. Given the associated long-
term toxicity of RT, it is now time to reassess
the appropriateness of preoperative RT as a
standard treatment for this stage of cancer.
RT has been shown to increase post-
operative complications, long-term toxicities
and impaired quality of life (QoL), com-
pared with surgery alone, and has not been
shown to improve overall survival. There are
marked differences between international
recommendations for preoperative RT in
rectal cancer (National Comprehensive
Cancer Network (NCCN), ESMO, National
Institute for Health and Care Excellence
(NICE)).3–5 This is reﬂected by a survey of
28 countries6 which reported 54 different
treatment policies for rectal cancer, support-
ing the view that there is no current
Strengths and limitations of this study
▪ A unique interventional study specific to low
rectal cancer.
▪ Will explore the contribution of the modern
abdominoperineal excision operation to cancer
outcomes.
▪ Strict quality assurance (QA) processes for
imaging, radiotherapy, surgery and pathology.
▪ Will establish if a future trial minimising radio-
therapy use in low rectal cancer is feasible.
▪ Study is limited by short follow-up period.
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consensus on preoperative treatment. RT can be asso-
ciated with signiﬁcant harm, including acute and
delayed severe toxicity, chronic pain, sexual dysfunction,
small bowel obstruction, radiation enteritis, urinary and
faecal incontinence and pelvic fractures.7 8 Subsequent
surgery is associated with increased morbidity and
wound complications after RT9 and reduced QoL.10 RT
can induce complete tumour regression but there
remains disparity between complete clinical response
rates and true complete pathological response rates such
that non-operative management is not widely
practised.11
The role of high-quality surgery in rectal cancer is well
known. An involved surgical resection margin is the
strongest predictor of locoregional recurrence and
reduced survival.12 Low rectal cancer often requires an
abdominoperineal excision (APE) procedure, which
sacriﬁces the rectum and anus necessitating a perman-
ent colostomy. National Bowel Cancer Audit suggests
that this procedure remains in common use (23.8% of
all rectal cancer operations in 2006/2007 and 2011/
2012 audit reports).13 14
Recent developments in reﬁning the present tech-
nique for conduct of APE are based on recognition of
the need for wide excision of the anal sphincter and
pelvic ﬂoor in appropriate patients as deﬁned by
MRI.15 16 The Low Rectal Cancer National Development
Programme (LOREC) ran between 2011 and 2014 and
was developed to train colorectal surgeons in appropri-
ate APE technique to improve outcomes.17 This so-called
extralevator approach has been shown to signiﬁcantly
reduce rates of margin involvement and intraoperative
tumour perforation over standard APE surgery18 yet has
not been scrutinised in the absence of preoperative RT.
It is notable that the studies used to inform current
guidelines which advocate preoperative RT had little
quality control over surgical technique. For example, the
German Rectal Cancer Study Group19 described no
quality control; the EORTC 229021 trial20 reported that
just 36% patients had surgery in the TME plane.
Although the recent MRC-CR07 study encouraged use
of TME techniques, only 52% of patients had surgery in
this optimal plane, which decreased to just 24% for
APE.21 Future studies should strictly monitor surgical
quality control as a deﬁned end point.
Equally, high-quality preoperative MRI (notably absent
in the chemoradiotherapy trials of Sauer et al19 and
Bosset et al20 that deﬁne current guidelines) has been
crucial to improved APE surgery through deﬁning the
relationship between the tumour and the predicted
resection margin. Preoperative MRI assessment of the
circumferential resection margin status is the most
important factor predicting risk of local recurrence and
survival.22 23
There is growing evidence to suggest that a highly
selective approach to the use of neoadjuvant RT may be
more appropriate than widespread application and the
need for further research is apparent. While many
would consider T4 disease and those with signiﬁcant
nodal burden to be indications for neoadjuvant therapy
the consensus is less apparent in the case of early T3
node negative tumours. RT is 80% more likely to be
used for abdominoperineal excision of the rectum
(APER) versus anterior resection (OR 0.20, 95% CI 0.18
to 0.23, p<0.01; P Quirke, personal communication).
This is more likely to be as long course RT, as national
audit shows that short course RT (5×5) is rarely used in
Europe for this indication. A more selective policy
towards neoadjuvant treatment depends on highly accur-
ate prediction of those patients in which there is a
potentially low risk of local recurrence. This challenge
in selecting subgroups with stage II and III disease who
would least beneﬁt from neoadjuvant treatment is evi-
denced by the wide variation in the use of preoperative
RT in the Welsh Bowel Cancer Audit.24 This showed that
the two units in Wales, UK achieving the lowest circum-
ferential margin involvement rates (both 3%) adminis-
tered neoadjuvant therapy to a diverging 30% and 86%
of patients, respectively. Trials are urgently required to
address this variation in practice.
METHODS AND ANALYSIS
This is a prospective 1:1 randomised surgical interven-
tion multicentre feasibility trial (2b exploration, IDEAL
recommendation) studying the omission of preoperative
long course RT in resectable locally advanced low rectal
cancer requiring APER for oncological reasons.
Recruitment is for 2 years with 12-month postsurgery
follow-up. The feasibility trial will determine the willing-
ness of participants and their clinicians to recruit to the
study together with testing the ability to collect study
data and its quality. It was considered important to deter-
mine these factors before launching the deﬁnitive trial
as it challenges current recommendations that patients
are considered for preoperative RT in locally advanced
rectal cancers involving the lower third of the rectum.
The feasibility trial will mirror the deﬁnitive trial design
to test all aspects of trial conduct. All patients will be
assessed by an MRI scan as per protocol.
Trial groups
Participants in this feasibility trial will be randomly
assigned using a computerised randomisation system
available as an internet-based application administered
by Swansea Trials Unit (STU), Swansea University.
Consenting patients will be randomised with equal prob-
ability to the intervention and control arms.
Intervention arm: ‘early surgery’
Participants randomised to receive early high-quality
APER. No preoperative RT treatment will be given to
these patients. Standard adjuvant chemotherapy after
surgery may be administered if indicated. Adjuvant post-
operative pelvic chemoradiation will be given if
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histopathological examination shows that the circumfer-
ential resection margin is ≤1 mm.
Comparative arm: ‘standard therapy’
Standard preoperative long course RT will be given to
participants. RT will be given as 45 Gy in 25 daily frac-
tions over 5 weeks. Intensity modulated radiotherapy
(IMRT) is permitted. Concurrent chemotherapy can be
given, if required, in accordance with standard care.
Participants will proceed to APER 8–12 weeks following
RT completion.
Adjuvant chemotherapy in standard and experimental arms
Prior to randomisation, based on pretreatment pelvic
MRI, treating teams will be asked to declare whether
they intend to administer postoperative adjuvant chemo-
therapy or not. This is to avoid an imbalance in the use
of adjuvant chemotherapy between the two arms of the
trial. Standard accepted indications will apply, for
example, nodal involvement, T4 disease or extramural
vascular invasion. Choice of chemotherapy will be in
accordance with each site’s current schedule and will be
recorded on the case report form (CRF). In practice,
little variation is anticipated.
Primary objective
To establish whether a future deﬁnitive trial comparing
surgery (modern APER) alone with standard care (pre-
operative long course RT then surgery) is feasible.
Secondary objectives
▸ To set up and test the infrastructure necessary to
perform a deﬁnitive trial.
▸ To test willingness of eligible participants to be rando-
mised to an early surgery-alone arm (with adjuvant
chemoradiation postsurgery if clinically indicated).
▸ To quantify the number of participants required for a
deﬁnitive trial using appropriate outcome measures.
▸ To test the ability to recruit, consent and retain parti-
cipants to the proposed intervention.
▸ To qualitatively explore reasons for non-recruitment.
▸ To test appropriateness and feasibility of collecting
the proposed outcome measures for a full trial.
The primary outcome measure will establish whether a
future deﬁnitive trial comparing surgery alone with
current standard care is feasible.
All secondary outcomes will be rehearsed during the
feasibility trial with a view to reﬁning (1) the process
and (2) the choice of outcomes for the main trial. The
ability to collect the following clinical, pathological, QoL
and health economic data will be tested.
A. EORTC QLQ-C30 and QLQ-CR29 QoL tools;
B. Health economic data collection tools (EuroQol-
5D-3L and Client Service Receipt Inventory);
C. Perioperative complication rates;
D. Rate of perineal wound healing at 3 months;
E. Time interval between surgery and initiation of adju-
vant chemotherapy after surgery (days);
F. Data sets for radiological staging, pathological
staging, RT delivery and surgical procedures to
include:
– Distance of tumour to CRM (mm),
– Plane of mesorectal and sphincter/levator excision
as proxy of surgical quality,
– Retrieval of macroscopic and cross-section photo-
graphs and histopathology slides for central review,
G. Detection of disease recurrence: local recurrence rate
and systemic recurrence rate (distant metastases).
Patients who decline trial inclusion will be invited to
participate in a qualitative semistructured interview to
explore the reasons for this which will inform the deﬁni-
tive trial design.
Site selection
This feasibility trial will take place in colorectal units
that have a high volume rectal cancer practice with high-
quality audited surgical results. Sites will be eligible to
participate based on current case volumes, surgical
quality (complete resection rates), clinical equipoise
with regard to the prescription of neoadjuvant treatment
for the participant entry criteria, RT target volume
audits and ability to perform MRI and histopathology to
the standard within the protocol.
Participant selection
Potential participants will be identiﬁed by their usual
clinicians in the colorectal cancer multidisciplinary team
meeting. They will be screened based on the
MRI-deﬁned inclusion criteria and suitability for RT
(and chemotherapy if applicable). The inclusion and
exclusion criteria are listed in box 1.
If eligible, participants will receive study information
from surgeon and oncologist and reinforced by a patient
information sheet. Participants will be offered a
minimum of 24 hours to consider enrolment before pro-
viding written informed consent. Informed consent will
be obtained before trial-speciﬁc procedures are per-
formed. A ﬂow chart for the trial is included in ﬁgure 1.
Randomisation
Participants will be randomised 1:1 immediately after
consent by a web-based method hosted by STU. From the
results of this feasibility trial, we will establish any stratify-
ing factors for randomisation in the future main trial.
Blinding
The trial statistician and independent radiologist and
pathologist undertaking central review will be blinded to
the treatment allocation until analysis has been under-
taken and approval has been received by the Trial
Steering Committee (TSC) to unlock the blinding.
Data collection and management
Data collection will be performed at baseline, after RT
treatment (if standard care group), before, during and
after surgery, and at the routine outpatient follow-up
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visits at 1, 3, 6 and 12 months after their surgery.
Participants will complete QoL questionnaires at the
same intervals.
Pathology photographs, histological sections and MRI
reports and scans will be collected.
Data will be collected on predesigned paper CRFs and
entered into an electronic data capture system hosted by
STU by site staff. The trial database will have built in
measures to assess data quality at time of input.
Statistical analysis and sample size
The sample size for this feasibility trial (n=80) is the
minimum number of participants considered necessary
to test the processes of data collection, and based on the
Box 1 Participant selection
Inclusion criteria
▸ Age 18 years or older;
▸ Histologically confirmed adenocarcinoma;
▸ Low rectal cancer defined as within 6 cm of anal verge on rigid sigmoidoscopy and considered to require abdominoperineal excision of
the rectum rather than restorative procedure (anterior resection);
▸ Potentially resectable local disease by surgery alone with clear margins as determined by MRI;
▸ Radiologically measurable or clinically evaluable disease;
▸ Clinical disease stage (MRI±endorectal ultrasound):
– cT3a/b (<5 mm) disease within 6 cm of anal verge;
– For tumours at / below level of puborectalis through full thickness of muscularis propria (cT2) disease at level of puborectalis;
▸ Involvement of internal anal sphincter or intersphincteric space without extension into adjacent levator plate;
▸ TanyN1 (resectable)—irregular border or mixed signal on MRI;
▸ WHO performance status 0, 1, or 2;
▸ Blood values:
– Neutrophil count ≥1500/mm3;
– Platelets ≥100 000/mm3;
– Haemoglobin >80 g/L;
– Total bilirubin ≤1.5×upper limit of normal (ULN);
– Aspartate aminotransferase and alanine transaminase ≤3×ULN;
– Creatinine ≤1.5×ULN;
– Negative pregnancy test;
▸ Patient of childbearing potential willing to employ adequate contraception;
▸ No other invasive malignancy ≤5 years prior to registration;
▸ No concurrent disease that, in the judgement of the clinician obtaining informed consent, would make the patient inappropriate for entry
into this trial;
▸ No chemotherapy within 5 years prior to registration;
▸ No prior pelvic radiation;
▸ Able and willing to give informed consent to participate.
Exclusion criteria
▸ Preoperative chemoradiotherapy absolutely indicated, for example, predicted CRM involvement (<1 mm) by primary or nodal disease, or
otherwise unresectable disease;
▸ cT3c or d (>5 mm);
▸ Adjacent organ involvement (prostate, seminal vesicles, sacrum or coccyx; T4b) requiring multivisceral resection/pelvic exenteration;
▸ For low tumours at level of puborectalis sling: lateral extension of tumour into external anal sphincter or beyond puborectalis sling into
levator plate (pT4a);
▸ Extramural vascular invasion on MRI;
Early stage rectal cancer (T1, T2 above level of levators) unless node positive;
▸ Locally perforated disease (T4a);
▸ Fistulating disease (vagina, perianal skin, adjacent hollow organ);
▸ Disease extrusion through anus;
▸ cN2 disease;
▸ Lateral pelvic/para-aortic lymphadenopathy;
▸ Unresectable metastatic disease (M1; potentially resectable disease permitted);
▸ Previous pelvic radiotherapy;
▸ Unfit for major surgery;
▸ Pregnancy;
Contraindication to MRI;
▸ Contraindication to standard chemotherapy (including drug interactions and glomerular filtration rate <50 mL/min at baseline);
▸ WHO performance status 3 or 4 or 5;
▸ Patients from vulnerable groups;
▸ Unwilling to consent to trial participation.
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recommendations of Lancaster et al25 with respect to the
number of patients required to yield meaningful esti-
mates of parameters of interest.
For the purposes of this feasibility trial, we will use stat-
istical test of hypothesis at 5% level of signiﬁcance with
CIs using the key parameters of interest. These include:
▸ The proportion of participants who agree to be
randomised.
▸ The proportion of participants undergoing surgery
who experience complications/toxicities.
▸ The proportion of participants for whom we can
collect outcomes for at 3, 6 and 12 months post-
treatment (ie, follow-up rates):
– The response rates to the questionnaires.
– Adherence/compliance rates.
▸ The SD of the QoL measures that are proposed for
the deﬁnitive trial.
▸ The effect size for the calculation of the sample size
for the deﬁnitive trial.
The decision to proceed to a full deﬁnitive trial will be
based on ACCEPT criteria.26 Our speciﬁc criteria for
progression to a full deﬁnitive trial are:
▸ Acceptable participant recruitment rates (>50% eli-
gible population).
▸ >60% of randomised participants receive the treat-
ment as allocated.
▸ >60% return rate of QoL questionnaires at 6 months.
▸ >50% compliance with return of economic analysis
data collection tools.
▸ Equivalent rates of CRM involvement are seen at
12 months.
Safety measures
Serious adverse events (SAEs) will be notiﬁed to STU
within 24 hours and to the Research Ethics Committee
(REC) within 15 days. A number of adverse events are
expected for patients undergoing RT and colorectal
surgery and will be exempted from reporting.
Figure 1 Trial flow chart.
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Quality assurance
Radiotherapy
National Radiotherapy Trials Quality Assurance
(RTTQA) Group will oversee the pretrial and on-trial
QA, which can be streamlined on request. Benchmark
cases (outlining and planning) will be assessed pretrial.
Centres wishing to use IMRT (or volumetric modulated
arc therapy) will be required to have completed the
IMRT credentialing programme. On-treatment veriﬁca-
tion by imaging the ﬁrst three fractions of treatment and
weekly thereafter is mandatory. The ﬁrst study patient
will have prospective review of contouring and planning
in real time as a minimum.
MRI
Sagittal T2-weighted turbo spin echo, large field of view
(FOV) axial T2 images of whole pelvis L5/S1, high-
resolution axial T2-weighted images and high-resolution
coronal T2-weighted images will be obtained at baseline.
The protocol mandates 3 mm slices with a 16–18 cm
FOV to optimise image quality. Images will be trans-
ferred securely via image exchange portal or equivalent
system for central review.
Surgery
Sites will be required to demonstrate satisfactory results
of APER surgery pretrial. The surgical technique is pro-
tocolised and requires wide excision of the pelvic ﬂoor.
Surgeons will declare their intended planes of excision
presurgery on a template which will be compared with
actual pathological plane of excision.
Pathology
A standardised protocol based on RCPath guidelines will
be used. Specimen photography is mandatory (whole
intact specimen and cross-sectional slices). Quality of the
mesorectal and sphincter/levator excision will be
assessed locally and then independently and blindly
assessed at the University of Leeds according to the
protocol.
Ethics and dissemination
The trial will be performed in accordance with the prin-
ciples of the Declaration of Helsinki and Good Clinical
Practice. The trial is approved by the Regional National
Health Service (NHS) Ethics Committee and local hos-
pital Research and Development permissions. Written
informed consent will be obtained from all participants.
All SAEs will be reported to STU, the ethics committee
and all sites will be notiﬁed of events.
It is recognised that there is a substantial body of evi-
dence in favour of preoperative long course RT in
locally advanced rectal cancer to minimise local recur-
rence. Risk factor for this are involved surgical resection
margins, T4 disease, N2 disease and extramural venous
invasion. Certain tumour characteristics mandate the
use of neoadjuvant treatment, particularly predicted sur-
gical resection margin involvement, so these patients will
not be eligible for this trial. The inclusion criteria have
been carefully selected to focus on the borderline group
of patients where high-quality early surgery alone may
well be sufﬁcient treatment, in conjunction with appro-
priate adjuvant therapies.
To minimise patient risk, potential sites will be
required to demonstrate evidence of high standards of
imaging, RT, pathology and surgical quality before eligi-
bility. On-trial QA will uphold these standards.
The trial will be scrutinised throughout by an inde-
pendent TSC who will also assume the role of the Data
Monitoring Committee. Particular attention will be given
to margin involvement rates. In the event of high-risk
pathological features for local pelvic recurrence being
detected after surgery (CRM≤1 mm), patients will be
offered adjuvant postoperative chemoradiation.
Publication of trial results in peer-reviewed journals
will include named members of the Trial Management
Group (TMG) meeting the three criteria of scholarship
(design, execution, analysis and/or interpretation of the
data), authorship (drafting, reviewing and revision of
the manuscript) and approval (approving the manu-
script to be published). Results will be disseminated
through the funding body and through Cancer
Research UK. Participants in the trial will be given a
copy of the results. A ﬁnal report will be written by the
TMG for the funding body and the REC.
DISCUSSION
The need to improve pretreatment risk stratiﬁcation was
further highlighted by Gunderson et al27 who suggested
patients at intermediate risk of LR (T1–2N1, T3N0)
might be overtreated with neoadjuvant (C)RT. It is
recognised that high-resolution MRI staging can accur-
ately predict those patients with good prognosis stage
III rectal tumours suitable for treatment with high-
quality surgery alone.22 The Mayo Clinic group reported
just 5.5% local recurrence rate in which APER com-
prised 38% of the series in a cohort of 655 patients
treated without RT, in which over 20% had stage III
rectal tumours.28 Data from Swansea reports equivalent
rates of margin involvement, local recurrence and sur-
vival in T3/T4 node positive rectal cancers in which
neoadjuvant treatment was reserved for predicted
margin involvement and signiﬁcant nodal disease,29
which is conﬁrmed by longitudinal analysis of this
selective approach to RT.30 Given the improvements in
CRM rates and local recurrence with the modern APE,
it is timely to scrutinise the role of neoadjuvant RT in
this setting. Rigorous prospective studies are required
not only to determine which subsets of stage II/III
rectal cancer beneﬁt from neoadjuvant therapy, but also
to deﬁne the contribution of modern surgery to local
disease control. Authorities support the need for trials
in stage II and III rectal cancer to minimise overtreat-
ment with RT.31 32 The potential patient beneﬁts of
having high-quality surgery without RT include
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improved QoL, reduced complications and long-term
morbidity and earlier access to postoperative adjuvant
systemic chemotherapy. Economic advantage from che-
moradiotherapy avoidance is estimated to be £6690 per
patient without including the cost of managing related
long-term complications (local data). This research is
integral to the future management of patients with
rectal cancer worldwide and carries international clin-
ical importance with the prospect of changing current
guidelines.
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